Antisense to transforming growth factor-β1 facilitates the apoptosis of macrophages in rat vein grafts

Journal of Vascular Research

Volumn 45, Issue 5, 2008, Pages 365-374

  Heaton, Nicholas S ^a   Wolff, Randal A ^a,b   Malinowski, Rita L ^a   Hullett, Debra A ^a   Hoch, John R ^a  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b WILLIAM S MIDDLETON MEMORIAL VETERANS HOSPITAL   (United States)

Author keywords

Gene knockdown; Hyperplasia; Restenosis; Transforming growth factor; Vein graft

Indexed keywords

CASPASE 3; CYCLINE; DNA; MESSENGER RNA; TRANSFORMING GROWTH FACTOR BETA1; ANTISENSE OLIGONUCLEOTIDE; CASP3 PROTEIN, RAT;

ADENOVIRUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTERY INTIMA PROLIFERATION; ARTICLE; CELL PROLIFERATION; CELL SPECIFICITY; CONTROLLED STUDY; DNA DAMAGE; ENZYME ACTIVITY; FEMORAL ARTERY; GENETIC TRANSDUCTION; GRAFT FAILURE; IMMUNOHISTOCHEMISTRY; MACROPHAGE; MALE; NONHUMAN; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRIORITY JOURNAL; RAT; VEIN GRAFT; VIRAL GENE THERAPY; ANIMAL; DNA FRAGMENTATION; ENZYME ACTIVATION; GENE THERAPY; GENE VECTOR; GENETICS; GRAFT OCCLUSION; HYPERPLASIA; LEWIS RAT; METABOLISM; METHODOLOGY; PATHOLOGY; TIME; TRANSPLANTATION; VEIN;

ADENOVIRIDAE; ANIMALS; APOPTOSIS; CASPASE 3; CELL PROLIFERATION; DNA FRAGMENTATION; ENZYME ACTIVATION; FEMORAL ARTERY; GENE THERAPY; GENETIC VECTORS; GRAFT OCCLUSION, VASCULAR; HYPERPLASIA; IMMUNOHISTOCHEMISTRY; MACROPHAGES; MALE; OLIGONUCLEOTIDES, ANTISENSE; PROLIFERATING CELL NUCLEAR ANTIGEN; RATS; RATS, INBRED LEW; TIME FACTORS; TRANSDUCTION, GENETIC; TRANSFORMING GROWTH FACTOR BETA1; VEINS;

EID: 50349091731     PISSN: 10181172     EISSN: None     Source Type: Journal    
DOI: 10.1159/000121406     Document Type: Article

References (31)

1. Faries PL, Logerfo FW, Arora S, Hook S, Pulling MC, Akbari CM, Campbell DR, Pomposelli FB Jr: A comparative study of alternative conduits for lower extremity revascularization: all-autogenous conduit versus prosthetic grafts. J Vasc Surg 2000;32:1080-1090.
2. Nguyen LL, Conte MS, Menard MT, Gravereaux EC, Chew DK, Donaldson MC, Whittemore AD, Belkin M: Infrainguinal vein bypass graft revision: factors affecting long-term outcome. J Vasc Surg 2004;40:916-923.
3. Angelini GD, Jeremy JY: Towards the treatment of saphenous vein bypass graft failure - a perspective of the Bristol Heart Institute. Biorheology 2002;39:491-499.
4. Mitra AK, Gangahar DM, Agrawal DK: Cellular, molecular and immunological mechanisms in the pathophysiology of vein graft intimal hyperplasia. Immunol Cell Biol 2006;84:115-124.
5. Khan R, Agrotis A, Bobik A: Understanding the role of transforming growth factor-beta1 in intimal thickening after vascular injury. Cardiovasc Res 2007;74:223-234.
6. White SJ, Newby AC: Gene therapy for all aspects of vein-graft disease. J Card Surg 2002;17:549-555.
7. Grossman M, Raper SE, Kozarsky K, Stein EA, Engelhardt JF, Muller D, Lupien PJ, Wilson JM: Successful ex vivo gene therapy directed to liver in a patient with familial hypercholesterolaemia. Nat Genet 1994;6:335-341.
8. Friedl R, Li J, Schumacher B, Hanke H, Waltenberger J, Hannekum A, Stracke S: Intimal hyperplasia and expression of transforming growth factor-beta1 in saphenous veins and internal mammary arteries before coronary artery surgery. Ann Thorac Surg 2004;78:1312-1318.
9. Ignotz RA, Massague J: Transforming growth factor-beta stimulates the expression of fibronectin and collagen and their incorporation into the extracellular matrix. J Biol Chem 1986;261:4337-4345.
10. Cipollone F, Fazia M, Mincione G, Iezzi A, Pini B, Cuccurullo C, Ucchino S, Spigonardo F, Di Nisio M, Cuccurullo F, Mezzetti A, Porreca E: Increased expression of transforming growth factor-beta 1 as a stabilizing factor in human atherosclerotic plaques. Stroke 2004;35:2253-2257.
11. Ward MR, Agrotis A, Kanellakis P, Hall J, Jennings G, Bobik A: Tranilast prevents activation of transforming growth factor-beta system, leukocyte accumulation, and neointimal growth in porcine coronary arteries after stenting. Arterioscler Thromb Vasc Biol 2002;22:940-948.
12. Singh NN, Ramji DP: The role of transforming growth factor-beta in atherosclerosis. Cytokine Growth Factor Rev 2006;17:487-499.
13. Chin BY, Petrache I, Choi AM, Choi ME: Transforming growth factor beta1 rescues serum deprivation-induced apoptosis via the mitogen-activated protein kinase (MAPK) pathway in macrophages. J Biol Chem 1999;274:11362-11368.
14. Furukawa Y, Matsumori A, Ohashi N, Shioi T, Ono K, Harada A, Matsushima K, Sasayama S: Anti-monocyte chemoattractant protein-1/monocyte chemotactic and activating factor antibody inhibits neointimal hyperplasia in injured rat carotid arteries. Circ Res 1999;84:306-314.
15. Wahl SM, Hunt DA, Wakefield LM, Cartney-Francis N, Wahl LM, Roberts AB, Sporn MB: Transforming growth factor type beta induces monocyte chemotaxis and growth factor production. Proc Natl Acad Sci USA 1987;84:5788-5792.
16. Owens GK, Kumar MS, Wamhoff BR: Molecular regulation of vascular smooth muscle cell differentiation in development and disease. Physiol Rev 2004;84:767-801.
17. Desmouliere A, Chaponnier C, Gabbiani G: Tissue repair, contraction, and the myofibroblast. Wound Repair Regen 2005;13:7-12.
18. Fukui D, Miyagawa S, Soeda J, Tanaka K, Urayama H, Kawasaki S: Overexpression of transforming growth factor beta1 in smooth muscle cells of human abdominal aortic aneurysm. Eur J Vasc Endovasc Surg 2003;25:540-545.
19. Hyman KM, Seghezzi G, Pintucci G, Stellari G, Kim JH, Grossi EA, Galloway AC, Mignatti P: Transforming growth factor-beta1 induces apoptosis in vascular endothelial cells by activation of mitogen-activated protein kinase. Surgery 2002;132:173-179.
20. Hoch JR, Stark VK, Turnipseed WD: The temporal relationship between the development of vein graft intimal hyperplasia and growth factor gene expression. J Vasc Surg 1995;22:51-58.
21. Wolff RA, Ryomoto M, Stark VE, Malinowski R, Tomas JJ, Stinauer MA, Hullett DA, Hoch JR: Antisense to transforming growth factor-beta1 messenger RNA reduces vein graft intimal hyperplasia and monocyte chemotactic protein 1. J Vasc Surg 2005;41:498-508.
22. Wolff RA, Malinowski RL, Heaton NS, Hullett DA, Hoch JR: Transforming growth factor-beta1 antisense treatment of rat vein grafts reduces the accumulation of collagen and increases the accumulation of h-caldesmon. J Vasc Surg 2006;43:1028-1036.
23. Brunner AM, Marquardt H, Malacko AR, Lioubin MN, Purchio AF: Site-directed mutagenesis of cysteine residues in the pro region of the transforming growth factor beta 1 precursor. Expression and characterization of mutant proteins. J Biol Chem 1989;264:13660-13664.
24. Wolf BB, Schuler M, Echeverri F, Green DR: Caspase-3 is the primary activator of apoptotic DNA fragmentation via DNA fragmentation factor-45/inhibitor of caspase-activated DNase inactivation. J Biol Chem 1999;274:30651-30656.
25. Ceballos KM, Nielsen GP, Selig MK, O'Connell JX: Is anti-h-caldesmon useful for distinguishing smooth muscle and myofibroblastic tumors? An immunohistochemical study. Am J Clin Pathol 2000;114:746-753.
26. Watanabe K, Tajino T, Sekiguchi M, Suzuki T: h-Caldesmon as a specific marker for smooth muscle tumors - comparison with other smooth muscle markers in bone tumors. Am J Clin Pathol 2000;113:663-668.
27. Bujak M, Frangogiannis NG: The role of TGF-beta signaling in myocardial infarction and cardiac remodeling. Cardiovasc Res 2007;74:184-195.
28. Leask A, Abraham DJ: TGF-beta signaling and the fibrotic response. FASEB J 2004;18:816-827.
29. McKarns SC, Letterio JJ, Kaminski NE: Concentration-dependent bifunctional effect of TGF-beta 1 on immunoglobulin production: a role for Smad3 in IgA production in vitro. Int Immunopharmacol 2003;3:1761-1774.
30. Pollman MJ, Naumovski L, Gibbons GH: Vascular cell apoptosis: cell type-specific modulation by transforming growth factor-beta1 in endothelial cells versus smooth muscle cells. Circulation 1999;99:2019-2026.
31. Zhang HY, Phan SH: Inhibition of myofibroblast apoptosis by transforming growth factor beta(1). Am J Respir Cell Mol Biol 1999;21:658-665.